Patents by Inventor John A. Kessler

John A. Kessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11851490
    Abstract: Disclosed are methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof. Particularly disclosed are methods for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof by administering to the subject a therapeutic agent such as an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: December 26, 2023
    Assignee: Northwestern University
    Inventors: Lixin Kan, John A. Kessler
  • Patent number: 11696896
    Abstract: Provided herein are immunomodulatory nanoparticles, compositions containing the same, and methods of use thereof, such as for the treatment of traumatic brain injury.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: July 11, 2023
    Assignee: Northwestern University
    Inventors: John A. Kessler, Sripadh B. Sharma
  • Publication number: 20210121413
    Abstract: Provided herein are immunomodulatory nanoparticles, compositions containing the same, and methods of use thereof, such as for the treatment of traumatic brain injury.
    Type: Application
    Filed: October 21, 2020
    Publication date: April 29, 2021
    Applicant: Northwestern University
    Inventors: John A. Kessler, Sripadh B. Sharma
  • Publication number: 20210047413
    Abstract: Disclosed are methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof. Particularly disclosed are methods for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof by administering to the subject a therapeutic agent such as an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 18, 2021
    Inventors: Lixin Kan, John A. Kessler
  • Patent number: 8697048
    Abstract: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: April 15, 2014
    Assignee: Northwestern University
    Inventors: Li-Ru Zhao, John A. Kessler
  • Publication number: 20120093784
    Abstract: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.
    Type: Application
    Filed: December 21, 2011
    Publication date: April 19, 2012
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Li-Ru Zhao, John A. Kessler
  • Patent number: 6011004
    Abstract: This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .alpha. (TFG-.alpha.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: January 4, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: John A. Kessler, Stuart C. Apfel
  • Patent number: 5648335
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: July 15, 1997
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva Univ.
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5633228
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: May 27, 1997
    Assignees: Cephalon, Inc.,, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5604202
    Abstract: This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor .varies. (TFG-.varies.), transforming growth factor .beta. (TGF-.beta.) and others to prevent drug-induced neuropathy.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: February 18, 1997
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: John A. Kessler, Stuart C. Apfel
  • Patent number: 5585348
    Abstract: This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: December 17, 1996
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Stanley M. Crain, Ke-fei Shen, John A. Kessler, Stuart C. Apfel
  • Patent number: 5569648
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: October 29, 1996
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5564250
    Abstract: An insulation system for metal buildings, having a roof structure formed by roof panels supported on parallel, relatively narrowly-spaced purlins which are, in turn, supported on parallel, relatively widely-spaced main support beams, comprises a plurality of adjacently positioned strips of insulating material suspended below the roof structure so as to form a relatively flat and continuous surface. The strips of insulating material are supported on a system of insulation support tube strings suspended from and extending in parallel spaced relation to selected purlins. Each insulation support tube string runs the entire length of the building in spaced and transverse relationship to the main support beams.
    Type: Grant
    Filed: January 10, 1994
    Date of Patent: October 15, 1996
    Inventor: John A. Kessler
  • Patent number: 5420112
    Abstract: The invention features a method of preventing or treating a peripheral neuropathy that results from a systemic disease (e.g., post-polio syndrome) or a toxic agent (e.g., a chemotherapeutic agent), and that is not caused by an abnormal insulin level in a mammal. The method involves administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to the mammal.
    Type: Grant
    Filed: April 16, 1993
    Date of Patent: May 30, 1995
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5357722
    Abstract: An insulation system for metal buildings, having a roof structure formed by roof panels supported on parallel, relatively narrowly-spaced purlins which are, in turn, supported on parallel, relatively widely-spaced main support beams, comprises a plurality of adjacently positioned strips of insulating material suspended below the roof structure so as to form a relatively flat and continuous surface. The strips of insulating material are supported on a system of insulation support tube strings suspended from and extending in parallel spaced relation to selected purlins. Each insulation support tube string runs the entire length of the building in spaced and transverse relationship to the main support beams.
    Type: Grant
    Filed: February 6, 1991
    Date of Patent: October 25, 1994
    Inventor: John A. Kessler